



2022 Targeted Therapies Patient Forum

Changes in the Field of Metastatic NSCLC

Dr. Fred Hirsch (Executive Director, Center for Thoracic Oncology at Tisch Cancer Institute, Mount Sinai, Professor of Medicine, Icahn School of Medicine, Associate Director, Biomarker Discovery for TCI)

TRANSCRIPT

Dr. Aakash: I will kick off the meeting by introducing our first speaker, Dr. Fred Hirsch, who will be talking about genetic testing in lung cancer. I think Dr. Hirsch needs no introduction to people who already work in the field. He's the Executive Director at the Center for Thoracic Oncology at Tisch Cancer Institute in Mount Sinai. He's also the Associate Director for Biomarker Discovery at the Tisch Cancer Institute. He is a well-renowned researcher who has moved the field forward through his outstanding contributions. Dr. Hirsch, thank you for joining us today.

Dr. Fred Hirsch: Thank you very much to everyone, and thanks for the invitation to be a part of this event. I'm very excited to talk with patients and patient's families. Particularly, these two groups are, of course, close to my heart, and I will try my best to make some complex issues understandable for everyone.

I have some disclosures. As probably everyone knows, we have seen amazing progress in treatment outcomes for Non-Small Cell Lung Cancer, particularly here in advanced stages, over the last two decades. When I came to the United States from Copenhagen, Denmark in the year 2000, that was the situation, with an overall survival of 11 months. Today, this is probably outdated already, but we can see here, we have gone through amazing progress. We started to talk about histology, then we came to maintenance therapy, then we came to molecularly targeted therapies, and then more recently, immunotherapy. Everything has contributed to this very encouraging progress in the outcome.

Here again, we started by just focusing on histologic subtypes, what we can see in the microscope, then we moved to molecular subtypes and genomic subtypes.